Company & Sponsor Intelligence

Otsuka Pharmaceutical Development & Commercialization, Inc.

Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.

Request enterprise analysis →

Indexed trials24

Recruiting1

Completed23

Countries1

Therapeutic footprint

adhdalzheimersautismbipolar_disorderdepressioneating_disordersepilepsyneurodevelopmental_otherother_psychiatryschizophrenia

Indexed studies

NCT07314333A Trial to Assess How Centanafadine Interacts With Stimulants in the Body
adhd · United StatesPHASE1

NCT07253441A Trial to Characterize Differences in Blood Levels of Different Lots of Centanafadine QD XR and to Understand the Effect of Food on Blood Levels
adhd · United StatesPHASE1

NCT01862640A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole in the Treatment of Alzheimer's Agitation
alzheimers · United StatesPHASE3

NCT07486895Trial to Demonstrate the Equivalence of Two Different Strengths of Oral Centanafadine Capsules in Healthy Subjects
adhd · United StatesPHASE1

NCT01994473Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia
schizophrenia · United StatesPHASE1

NCT05536414Trial of Centanafadine Efficacy and Safety as Monotherapy or as Adjunct to SSRI in Adults With Major Depressive Disorder
depression · United StatesPHASE2

NCT01052077Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder
depression · United StatesPHASE2

NCT07549581A Study of SEP-380135 in Adults With Schizophrenia or Major Depressive Episode
depression · United StatesPHASE1

NCT03605849A Trial Evaluating the Long-term Safety and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder
adhd · United StatesPHASE3

NCT04786730A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine Capsules in Pediatric Subjects With Attention-deficit Hyperactivity Disorder
adhd · United StatesPHASE1

NCT04100096A Trial of Brexpiprazole in the Treatment of Borderline Personality Disorder
other_psychiatry · United StatesPHASE2

NCT01416441Safety and Tolerability Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder
neurodevelopmental_other · United StatesPHASE3

Intelligence layer updated: 2026-10-29 06:17:44.639239+00:00

Enterprise intelligence

Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.

Request comparative intelligence →